Seminar – James D. Winkler, Ph.D.

Event Date & Time

June 8, 2022 at 12 Noon


MED 444B

Event Details:



Wednesday, June 8, 2022

12:00pm – 444B LSOM

James Winkler, Ph.D.
Chief Scientific Officer
OnKure Therapeutics
Boulder, Colorado



Save to Calendar

Add to Calendar

About the Speaker(s)

OnKure is a clinical-stage biopharmaceutical company pioneering a novel Class-1 selective histone deacetylase inhibitor for the treatment of solid tumor cancers and has appointment of James Winkler, Ph.D. as Chief Scientific Officer.

Dr. Winkler brings over 35 years of experience in preclinical and clinical research as well as expertise in translational analysis for novel precision medicine therapeutics in oncology. Prior to joining OnKure, Dr. Winkler worked for several successful oncology-focused organizations. He joined Arvinas as the Chief Scientific Officer, helping the new company focus on a novel technology, validating and further advancing this technology, and building a growing preclinical pipeline, enabling Arvinas to go public. At Array BioPharma, Dr. Winkler served as Vice President of Biology, leading a discovery and early development organization with an impressive record of accomplishment, placing over 16 drugs into the clinic, several of which moved to Phase 3 and registration. He has also held roles in companies of varying size, including Johnson & Johnson, SmithKline Beecham, GlaxoSmithKline and FORMA Therapeutics, where he gained extensive experience building and leading teams, and managing programs from target validation and early drug discovery through to translational medicine and clinical development. He received his Ph.D. in Pharmacology from the Medical College of Pennsylvania and did his postdoctoral training with Dr. Stanley Crooke at SmithKline Beecham.